Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.90%
median of 617 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Kyverna Therapeutics, Inc.
Market Cap
$378.64M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$376.61M
Gross Margin
95.50%
TTM Avg
97.75%
3Y Avg
98.88%
5Y Avg
1.50%
Market Cap
$381.71M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$383.33M
Gross Margin
69.59%
TTM Avg
67.69%
3Y Avg
68.42%
5Y Avg
70.65%
Market Cap
$370.48M
Gross Margin
25.47%
TTM Avg
27.02%
3Y Avg
15.55%
5Y Avg
5.84%
Market Cap
$401.40M
Gross Margin
68.83%
TTM Avg
69.91%
3Y Avg
69.67%
5Y Avg
69.68%
Market Cap
$354.49M
Gross Margin
99.32%
TTM Avg
95.85%
3Y Avg
93.96%
5Y Avg
99.79%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | $378.64M | 0.00% | 0.00% | 0.00% | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $376.61M | 95.50% | 97.75% | 98.88% | 1.50% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $381.71M | 0.00% | 0.00% | 0.00% | 0.00% |
| Orthofix Medical Inc. (OFIX)vs › | $383.33M | 69.59% | 67.69% | 68.42% | 70.65% |
| Canopy Growth Corporation (CGC)vs › | $370.48M | 25.47% | 27.02% | 15.55% | 5.84% |
| Myriad Genetics, Inc. (MYGN)vs › | $401.40M | 68.83% | 69.91% | 69.67% | 69.68% |
| Embecta Corp. (EMBC)vs › | $355.08M | 59.89% | 63.90% | 65.83% | 67.05% |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $354.49M | 99.32% | 95.85% | 93.96% | 99.79% |
| Ocugen, Inc. (OCGN)vs › | $357.76M | 45.86% | 48.66% | 71.42% | -2398.51% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $353.28M | 93.73% | 92.44% | 93.34% | 78.89% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | -32.62% |
